Neutralizing human anti-IGFR antibody
US7667021B2 · kind B2 · utility
2Cited by
33References
46Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 13, 2006 |
| Grant date | Feb 23, 2010 |
| Priority date | — |
| Expiry date | Jun 14, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.